ArticleEmergency radiology2025
Safety and efficacy of the Abre™ venous stent in treating thoracic venous stenosis/occlusion: a single-center experience.
Article in Emergency radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the clinical outcomes, technical success, and complications associated with the placement of Abre™ venous stents for central venous stenosis/occlusion (CVS/CVO). MATERIALS AND
methodsA retrospective review was conducted, identifying 21 patients who underwent Abre™ venous stent placement for SVC syndrome at a single institution. Demographic and clinical data were collected, including stent configurations, procedural details, and follow-up outcomes. Primary stent patency, symptom resolution, and survival rates were analyzed. Survival curves were generated using Kaplan-Meier analysis, and complications were recorded.
resultsFacial and/or upper extremity edema was present in all patients, and malignancy accounted for SVC syndrome in 71.4% of cases, with lung cancer as the predominant etiology (66.6%). The technical success rate was 100%. Clinical symptom resolution was achieved in all patients. The 30-day mortality rate was 23.8%, with all cases involving oncology patients. At six months, cross-sectional imaging showed a primary stent patency rate of 93%, and this remained stable through 12 months. The mean survival time for the cancer subgroup was 337.2 ± 343 days, while the overall cohort mean was 885.8 ± 453.7 days.
conclusionThe Abre™ venous stent demonstrates potential as an effective stent for SVC syndrome, achieving high symptom relief and patency rates. However, further long-term studies and randomized controlled trials are necessary to validate these findings.
Indexed as
Identifiers
39924622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.